---
title: Use of Clonidine to Prevent Withdrawal Following Prolonged Dexmedetomidine Infusions
nct_id: NCT02404077
overall_status: COMPLETED
sponsor: Joseph D. Tobias
study_type: OBSERVATIONAL
primary_condition: Sedation
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT02404077.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT02404077"
ct_last_update_post_date: 2017-04-20
last_seen_at: "2026-05-12T07:14:16.125Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Use of Clonidine to Prevent Withdrawal Following Prolonged Dexmedetomidine Infusions

**NCT ID:** [NCT02404077](https://clinicaltrials.gov/study/NCT02404077)

## Key Facts

- **Status:** COMPLETED
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 712
- **Lead Sponsor:** Joseph D. Tobias
- **Conditions:** Sedation
- **Start Date:** 2015-04
- **Completion Date:** 2017-03
- **CT.gov Last Update:** 2017-04-20

## Brief Summary

The investigators' clinical practice makes use of oral clonidine as a means of transitioning from intravenous dexmedetomidine following prolonged infusions (more than 3-5 days). Although this is common clinical practice, there is limited clinical data to demonstrate the efficacy of this technique and to provide clonidine dosing guidelines. The purpose of this study is to retrospectively review the investigators' experience with the use of oral clonidine to prevent withdrawal following the prolonged administration of dexmedetomidine.

## Eligibility

- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Patients who received clonidine during the transition from dexmedetomidine.

Exclusion Criteria:

* None
```

## Arms

- **Clonidine** — Patients who received clonidine following prolonged dexmedetomidine infusions

## Interventions

- **Clonidine** (DRUG)

## Primary Outcomes

- **Evidence of withdrawal** _(time frame: Twice a day from the first day of taper of dexmedetomidine until 72 hrs. after the last dose)_ — Withdrawal is assessed using the Withdrawal Assessment Tool-1 (WAT-1). The 19-item assessment consists of (1) a review of the patient's record for the past 12 hours, (2) direct observation of the patient for 2 minutes, (3) patient assessment during a progressive stimulated exam routinely performed to assess level of consciousness at the beginning of each 12-hour shift, and finally (4) assessment of post-stimulus recovery.

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT02404077.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT02404077*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*